Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Broad Center for Mendelian Genomics, |
RCV001005003 | SCV001164564 | likely pathogenic | Retinitis pigmentosa 74 | 2018-12-03 | criteria provided, single submitter | research | The heterozygous p.Tyr229His variant in BBS2 was identified by our study in the compound heterozygous state, with a VUS, in one individual with retinitis pigmentosa. Trio exome analysis showed this variant to be de novo. The p.Tyr229His variant in BBS2 has not been previously reported in individuals with retinitis pigmentosa but has been identified in 0.002527% (7/277022) of chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs778543585). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PM2, PP3, PS2 (Richards 2015). |
Invitae | RCV001061887 | SCV001226647 | uncertain significance | Bardet-Biedl syndrome | 2022-04-07 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 229 of the BBS2 protein (p.Tyr229His). This variant is present in population databases (rs778543585, gnomAD 0.004%). This missense change has been observed in individual(s) with clinical features of BBS2-related conditions (PMID: 31054281). ClinVar contains an entry for this variant (Variation ID: 813999). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001832327 | SCV002089296 | uncertain significance | Bardet-Biedl syndrome 2 | 2020-02-13 | no assertion criteria provided | clinical testing |